Ore Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ore Pharmaceuticals Inc.

ORXE 0.193

+1.8%

Aug 18 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Mike McFarland	3/17/2009 10:44:46 PM
	Read Replies (1) of 50

accumulated deficit $373M, Mark J. Gabrielson is now President and CEO. The annual report mentions method of use patent applications for tiapamil and romarazit, as well as positive results in a pilot animal study for GL1001 in radiation enteritis. Results for the next trial of 1001 for ulcerative colitis wont be til mid to late 2010--that Ib/IIa trial is slated to start mid year. There is a short blurb about there being 'preliminary evidence' that GL1001 'may be useful' in Crohn's disease. Market cap today, $1.75M--less than half a percent of what they've burned over the years.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next